<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01055457</url>
  </required_header>
  <id_info>
    <org_study_id>CR-1650</org_study_id>
    <nct_id>NCT01055457</nct_id>
  </id_info>
  <brief_title>Vistakon Investigational Multi-purpose Contact Lens Care Solution.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares an investigational contact lens care multi-purpose solution to a
      currently marketed multi-purpose solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2009</start_date>
  <completion_date type="Actual">May 1, 2010</completion_date>
  <primary_completion_date type="Actual">May 1, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slit Lamp Findings (SLF)</measure>
    <time_frame>Up to 3 months Post Lens Wear</time_frame>
    <description>Slit Lamp Findings were assessed for each subject eye at baseline, 1-day, 1-week, 2-week, 1-month and 3-month follow-up evaluations. SLF consisted of Edema, Corneal Neovascularization, Cornela Staining, Injection, Tarsal Abnormalities and Other findings; each was graded on a 5-likert Scale (Grade: None, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe). The number of eyes with Grade 2 or higher across all time points for each SLF variable was reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Distance Visual Acuity (LogMAR)</measure>
    <time_frame>Up to 3 Months Post Lens Wear</time_frame>
    <description>Distance Visual Acuity (LogMAR) was assessed for each subject eye at 1-week, 2-week, 1-month and 3-month follow-up evaluations. The average Visual Acuity (LogMAR) for each time point and lens was reported.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">315</enrollment>
  <condition>Contact Lens Wear</condition>
  <arm_group>
    <arm_group_label>Experimental Multi-Purpose Solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>contact lens care solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ReNu MultiPlus Multi-Purpose Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>contact lens care solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vistakon Investigational Multi-Purpose Solution II</intervention_name>
    <description>contact lens care solution</description>
    <arm_group_label>Experimental Multi-Purpose Solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReNu MultiPlus Multi-Purpose Solution</intervention_name>
    <description>contact lens care solution</description>
    <arm_group_label>ReNu MultiPlus Multi-Purpose Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must be an adapted contact lens wearer

          -  best corrected distance visual acuity must be 20/25 or better in each eye

          -  must be wearing their habitual lenses on a daily wear basis

          -  must be willing to refrain from swimming during the study

        Exclusion Criteria:

          -  any systemic diseases that may interfere with contact lens wear

          -  any clinically significant ocular disease

          -  any ocular infection

          -  use of certain medications

          -  any grade 2 or greater slit lamp findings

          -  any know sensitivity to marketed contact lens care solutions

          -  currently pregnant or lactating

          -  monovision corrected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jamestown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vestal</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moon</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2010</study_first_submitted>
  <study_first_submitted_qc>January 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2010</study_first_posted>
  <results_first_submitted>August 10, 2016</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2017</results_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 315 subjects were enrolled in this study. Of the enrolled subjects 20 did not meet the eligibility criteria and 295 subjects were randomized to treatment.Of the randomized subjects 16 were discontinued from the study, while 279 completed the study.</recruitment_details>
      <pre_assignment_details>Allocation of subjects to the 5 contact lenses was fairly balanced ranging from 57 to 61 subjects per lens, while the allocation of subjects to solution was 2:1 for the test and control solution respectively.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Solution1 (Etafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="P2">
          <title>Solution1 (Comfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="P3">
          <title>Solution1 (Balafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="P4">
          <title>Solution1 (Lotrafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="P5">
          <title>Solution1 (Galyfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="P6">
          <title>Solution2 (Etafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="P7">
          <title>Solution2 (Comfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="P8">
          <title>Solution2 (Balafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="P9">
          <title>Solution2 (Lotrafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="P10">
          <title>Solution2 (Galyfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="18"/>
                <participants group_id="P7" count="19"/>
                <participants group_id="P8" count="19"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="36"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="18"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Disinterest</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discomfort</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects that were dispensed a study lens and solution.</population>
      <group_list>
        <group group_id="B1">
          <title>Solution 1 (Etafilcon A)</title>
          <description>All subjects that were dispensed solution 1 and the etafilcon A lens.</description>
        </group>
        <group group_id="B2">
          <title>Solution 1 (Comfilcon A)</title>
          <description>All subjects that were dispensed solution 1 and the comfilcon A study lens.</description>
        </group>
        <group group_id="B3">
          <title>Solution 1 (Balafilcon A)</title>
          <description>All subjects that were dispensed solution 1 and the balafilcon A study lens.</description>
        </group>
        <group group_id="B4">
          <title>Solution 1 (Lotrafilcon A)</title>
          <description>All subjects that were dispensed solution 1 and the lotrafilcon A study lens.</description>
        </group>
        <group group_id="B5">
          <title>Solution 1 (Galyfilcon A)</title>
          <description>All subjects that were dispensed solution 1 and the galyfilcon A study lens.</description>
        </group>
        <group group_id="B6">
          <title>Solution 2 (Etafilcon A)</title>
          <description>All subjects that were dispensed solution 2 and etafilcon A study lens.</description>
        </group>
        <group group_id="B7">
          <title>Solution 2 (Comfilcon A)</title>
          <description>All subjects that were dispensed solution 2 and the comfilcon A study lens.</description>
        </group>
        <group group_id="B8">
          <title>Solution 2 (Balafilcon A)</title>
          <description>All subjects that were dispensed solution 2 and balafilcon A study lens.</description>
        </group>
        <group group_id="B9">
          <title>Solution 2 (Lotrafilcon A)</title>
          <description>All subjects that were dispensed solution 2 and the lotrafilcon A study lens.</description>
        </group>
        <group group_id="B10">
          <title>Solution 2 (Galyfilcon A)</title>
          <description>All subjects that were dispensed solution 2 and the galyfilcon A study lens.</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="41"/>
            <count group_id="B6" value="18"/>
            <count group_id="B7" value="19"/>
            <count group_id="B8" value="19"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="20"/>
            <count group_id="B11" value="295"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Solution 1(etafilcon A)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.17" spread="8.692"/>
                    <measurement group_id="B2" value="31.58" spread="9.459"/>
                    <measurement group_id="B3" value="32.16" spread="8.526"/>
                    <measurement group_id="B4" value="29.45" spread="9.333"/>
                    <measurement group_id="B5" value="29.10" spread="7.993"/>
                    <measurement group_id="B6" value="32.48" spread="7.845"/>
                    <measurement group_id="B7" value="29.95" spread="6.417"/>
                    <measurement group_id="B8" value="34.26" spread="8.738"/>
                    <measurement group_id="B9" value="30.10" spread="9.554"/>
                    <measurement group_id="B10" value="32.15" spread="8.079"/>
                    <measurement group_id="B11" value="30.89" spread="9.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="13"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="189"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="41"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Slit Lamp Findings (SLF)</title>
        <description>Slit Lamp Findings were assessed for each subject eye at baseline, 1-day, 1-week, 2-week, 1-month and 3-month follow-up evaluations. SLF consisted of Edema, Corneal Neovascularization, Cornela Staining, Injection, Tarsal Abnormalities and Other findings; each was graded on a 5-likert Scale (Grade: None, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe). The number of eyes with Grade 2 or higher across all time points for each SLF variable was reported.</description>
        <time_frame>Up to 3 months Post Lens Wear</time_frame>
        <population>All subjects that completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Solution1 (Etafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O2">
            <title>Solution1 (Comfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O3">
            <title>Solution1 (Balafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O4">
            <title>Solution1 (Lotrafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O5">
            <title>Solution1 (Galyfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O6">
            <title>Solution2 (Etafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O7">
            <title>Solution2 (Comfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O8">
            <title>Solution2 (Balafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O9">
            <title>Solution2 (Lotrafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O10">
            <title>Solution2 (Galyfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Slit Lamp Findings (SLF)</title>
          <description>Slit Lamp Findings were assessed for each subject eye at baseline, 1-day, 1-week, 2-week, 1-month and 3-month follow-up evaluations. SLF consisted of Edema, Corneal Neovascularization, Cornela Staining, Injection, Tarsal Abnormalities and Other findings; each was graded on a 5-likert Scale (Grade: None, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe). The number of eyes with Grade 2 or higher across all time points for each SLF variable was reported.</description>
          <population>All subjects that completed the study.</population>
          <units>eyes (2 per subject)</units>
          <param>Number</param>
          <units_analyzed>Subject eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subject eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Neovascularization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Corneal Staining</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="28"/>
                    <measurement group_id="O9" value="12"/>
                    <measurement group_id="O10" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tarsal Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="6"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Distance Visual Acuity (LogMAR)</title>
        <description>Distance Visual Acuity (LogMAR) was assessed for each subject eye at 1-week, 2-week, 1-month and 3-month follow-up evaluations. The average Visual Acuity (LogMAR) for each time point and lens was reported.</description>
        <time_frame>Up to 3 Months Post Lens Wear</time_frame>
        <population>All subjects that completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Solution1 (Etafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O2">
            <title>Solution1 (Comfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O3">
            <title>Solution1 (Balafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O4">
            <title>Solution1 (Lotrafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O5">
            <title>Solution1 (Galyfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
          </group>
          <group group_id="O6">
            <title>Solution2 (Etafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O7">
            <title>Solution2 (Comfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O8">
            <title>Solution2 (Balafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O9">
            <title>Solution2 (Lotrafilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
          <group group_id="O10">
            <title>Solution2 (Galyfilcon A)</title>
            <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Distance Visual Acuity (LogMAR)</title>
          <description>Distance Visual Acuity (LogMAR) was assessed for each subject eye at 1-week, 2-week, 1-month and 3-month follow-up evaluations. The average Visual Acuity (LogMAR) for each time point and lens was reported.</description>
          <population>All subjects that completed the study.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Subjects Eyes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="38"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Subjects Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="74"/>
                <count group_id="O5" value="76"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="36"/>
                <count group_id="O9" value="40"/>
                <count group_id="O10" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.033" spread="0.0601"/>
                    <measurement group_id="O2" value="-0.042" spread="0.0630"/>
                    <measurement group_id="O3" value="-0.037" spread="0.0563"/>
                    <measurement group_id="O4" value="-0.040" spread="0.0665"/>
                    <measurement group_id="O5" value="-0.029" spread="0.0615"/>
                    <measurement group_id="O6" value="-0.055" spread="0.0580"/>
                    <measurement group_id="O7" value="-0.033" spread="0.0601"/>
                    <measurement group_id="O8" value="-0.040" spread="0.0540"/>
                    <measurement group_id="O9" value="-0.045" spread="0.0685"/>
                    <measurement group_id="O10" value="-0.012" spread="0.0619"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.045" spread="0.0642"/>
                    <measurement group_id="O2" value="-0.041" spread="0.0663"/>
                    <measurement group_id="O3" value="-0.047" spread="0.0592"/>
                    <measurement group_id="O4" value="-0.039" spread="0.0649"/>
                    <measurement group_id="O5" value="-0.037" spread="0.0594"/>
                    <measurement group_id="O6" value="-0.058" spread="0.0585"/>
                    <measurement group_id="O7" value="-0.045" spread="0.0642"/>
                    <measurement group_id="O8" value="-0.051" spread="0.0625"/>
                    <measurement group_id="O9" value="-0.031" spread="0.0551"/>
                    <measurement group_id="O10" value="-0.030" spread="0.0595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.045" spread="0.0623"/>
                    <measurement group_id="O2" value="-0.042" spread="0.0644"/>
                    <measurement group_id="O3" value="-0.033" spread="0.0658"/>
                    <measurement group_id="O4" value="-0.040" spread="0.0628"/>
                    <measurement group_id="O5" value="-0.037" spread="0.0595"/>
                    <measurement group_id="O6" value="-0.068" spread="0.0541"/>
                    <measurement group_id="O7" value="-0.045" spread="0.0623"/>
                    <measurement group_id="O8" value="-0.026" spread="0.0534"/>
                    <measurement group_id="O9" value="-0.031" spread="0.0626"/>
                    <measurement group_id="O10" value="-0.032" spread="0.0610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.045" spread="0.0673"/>
                    <measurement group_id="O2" value="-0.031" spread="0.0609"/>
                    <measurement group_id="O3" value="-0.039" spread="0.0617"/>
                    <measurement group_id="O4" value="-0.038" spread="0.0607"/>
                    <measurement group_id="O5" value="-0.031" spread="0.0613"/>
                    <measurement group_id="O6" value="-0.051" spread="0.0668"/>
                    <measurement group_id="O7" value="-0.045" spread="0.0673"/>
                    <measurement group_id="O8" value="-0.034" spread="0.0567"/>
                    <measurement group_id="O9" value="-0.014" spread="0.0618"/>
                    <measurement group_id="O10" value="-0.040" spread="0.0614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the duration of the study. Approximately 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Solution1 (Etafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="E2">
          <title>Solution1 (Comfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="E3">
          <title>Solution1 (Balafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="E4">
          <title>Solution1 (Lotrafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="E5">
          <title>Solution1 (Galyfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 1 was an experimental multi-purpose solution.</description>
        </group>
        <group group_id="E6">
          <title>Solution2 (Etafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="E7">
          <title>Solution2 (Comfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="E8">
          <title>Solution2 (Balafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="E9">
          <title>Solution2 (Lotrafilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
        <group group_id="E10">
          <title>Solution2 (Galyfilcon A)</title>
          <description>Subjects were random first randomized to 1 of 5 contact lenses and then randomized to receive 1 of 2 contact lens solutions. Solution 2 was ReNu MultiPlus multi-purpose solution.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous Hemorrhage / Retinal Detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis - Bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Symptoms/ Complaints</sub_title>
                <description>Symptoms and complaints requiring treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kristy Canavan, O.D.- PRINCIPAL RESEARCH OPTOMETRIST, Clin Ops</name_or_title>
      <organization>Johson &amp; Johnson Vision Care Inc.</organization>
      <phone>904-443-3500</phone>
      <email>KCANAVA2@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

